Source: Annual Congress 2012 - Diffuse parenchymal lung disease II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. McAllister, P. Macfarlane, G. Stewart, A. Robson, W. Wallace, J. Murchison, J. Simpson, N. Hirani (Edinburgh, Newcastle-upon-Tyne, United Kingdom). Disease progression according to IPF phenotype. Eur Respir J 2012; 40: Suppl. 56, 3634

Member's Comments

No comment yet.

Related content which might interest you: Disease progression patterns in COPD Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 Disease pathology in interstitial lung disease Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021 Disease progression at 12 months does not predict future outcomes in IPF patients: Analysis from the Australian IPF Registry Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Disease severity in COPD patients Source: Annual Congress 2003 - Staging and outcome in COPD Year: 2003 Disease progression in early idiopathic pulmonary fibrosis: Insights from the Australian IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Does the BTNL2 genotype influence the course of disease in Danish sarcoidosis patients? Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Prevalence of Poor Disease Control in Patients with severe COPD according to GOLD 2021 Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021 Study of IPF relatives as a method of early diagnosis of ILD disease Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Lung function reversibility as a predictor of disease progression in COPD Source: International Congress 2017 – Markers of COPD progression Year: 2017 Disease patterns in connective tissue disease-associated interstitial lung disease: a population based study Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019 Short telomere length and its association with risk for COPD and emphysema severity: Korean Obstructive Lung Disease (KOLD) cohort study Source: International Congress 2017 – Markers of COPD progression Year: 2017 Anemia in COPD patients of Korean obstructive lung disease (KOLD) cohort Source: International Congress 2015 – Multidimensional analysis of respiratory problems Year: 2015 SP-C deficiency: Three different phenotypes for the same mutation Source: International Congress 2015 – Paediatric bronchology Year: 2015 Disease course and outcome of progressive interstitial lung disease in systemic sclerosis Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Disease progression in IPF assessed using pulmonary function tests and functional respiratory imaging (FRI) – A pilot study Source: International Congress 2014 – COPD and PAH related imaging Year: 2014 Relation of various parameters to the survival rate in stage 0 to stage IIa chronic obstructive pulmonary disease (COPD) according to the GOLD guidelines Source: Eur Respir J 2003; 22: Suppl. 45, 578s Year: 2003 Clinical course and outcome of vasculitis related interstitial lung disease Source: International Congress 2014 – ILDs 2 Year: 2014 Prognostic significance of neutrophil to lymphocyte ratio in chronic obstructive pulmonary disease Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014 Defining progression in non-IPF ILD Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021